Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freel, E. M.
Right arrow Articles by Connell, J. M.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freel, E. M.
Right arrow Articles by Connell, J. M.C.
J Am Soc Nephrol 15:1993-2001, 2004
© 2004 American Society of Nephrology


FRONTIERS IN NEPHROLOGY

Mechanisms of Hypertension: The Expanding Role of Aldosterone

E. Marie Freel and John M.C. Connell

MRC Blood Pressure Group, Division of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, United Kingdom

Correspondence to Prof. John M.C Connell, MRC Blood Pressure Group, Western Infirmary, Glasgow, G11 6NT, UK. Phone: +44-141-211-2108; Fax: +44-141-211-1763; E-mail: j.connell{at}clinmed.gla.ac.uk

ABSTRACT. Hypertension is a common disorder that affects a large heterogeneous patient population. Subgroups can be identified on the basis of their responses to hormonal and biologic stimuli. These subgroups include low-renin hypertensives and nonmodulators. Aldosterone, the principal human mineralocorticoid, is increasingly recognized as playing a significant role in cardiovascular morbidity, and its role in hypertension has recently been reevaluated with studies that suggest that increased aldosterone biosynthesis (as defined by an elevated aldosterone to renin ratio) is a key phenotype in up to 15% of individuals with hypertension. It was reported previously that a polymorphism of the gene (C to T conversion at position –344) encoding aldosterone synthase is associated with hypertension, particularly in individuals with a high ratio. However, the most consistent association with this variant is a relative impairment of adrenal 11{beta}-hydroxylation. This review explores the evidence for this and provides a hypothesis linking impaired 11{beta}-hydroxylation and hypertension with a raised aldosterone to renin ratio. It is also speculated that there is substantial overlap between this group of patients and previously identified low-renin hypertensives and nonmodulators. Thus, these groups may form a neurohormonal spectrum reflecting different stages of hypertension or indeed form sequential steps in the natural history of hypertension in genetically susceptible individuals.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
B. Klanke, N. Cordasic, A. Hartner, R. E. Schmieder, R. Veelken, and K. F. Hilgers
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension
Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3456 - 3463.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Bagi, N. Erdei, and A. Koller
High intraluminal pressure via H2O2 upregulates arteriolar constrictions to angiotensin II by increasing the functional availability of AT1 receptors
Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H835 - H841.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Catena, G. Colussi, R. Lapenna, E. Nadalini, A. Chiuch, P. Gianfagna, and L. A. Sechi
Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism
Hypertension, November 1, 2007; 50(5): 911 - 918.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. Pojoga, N. S. Kolatkar, J. S. Williams, T. S. Perlstein, X. Jeunemaitre, N. J. Brown, P. N. Hopkins, B. A. Raby, and G. H. Williams
{beta}-2 Adrenergic Receptor Diplotype Defines a Subset of Salt-Sensitive Hypertension
Hypertension, November 1, 2006; 48(5): 892 - 900.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Bochud, J. Nussberger, P. Bovet, M. R. Maillard, R. C. Elston, F. Paccaud, C. Shamlaye, and M. Burnier
Plasma Aldosterone Is Independently Associated With the Metabolic Syndrome
Hypertension, August 1, 2006; 48(2): 239 - 245.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
V. Vallon, D. Y. Huang, F. Grahammer, A. W. Wyatt, H. Osswald, P. Wulff, D. Kuhl, and F. Lang
SGK1 as a determinant of kidney function and salt intake in response to mineralocorticoid excess
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R395 - R401.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
J. M C Connell and E. Davies
The new biology of aldosterone
J. Endocrinol., July 1, 2005; 186(1): 1 - 20.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Blanco-Rivero, V. Cachofeiro, V. Lahera, R. Aras-Lopez, I. Marquez-Rodas, M. Salaices, F. E. Xavier, M. Ferrer, and G. Balfagon
Participation of Prostacyclin in Endothelial Dysfunction Induced by Aldosterone in Normotensive and Hypertensive Rats
Hypertension, July 1, 2005; 46(1): 107 - 112.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. S. Francis and W.H. W. Tang
Should we consider aldosterone as the primary screening target for preventing cardiovascular events?
J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1249 - 1250.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP